May 10, 2013
/PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO) today announced that it has priced an underwritten public offering of 9.5 million shares of its common stock, at a price to the public of
per share for gross proceeds of
. Net proceeds, after underwriting discount and other estimated fees and expenses payable by the Company, are expected to be approximately
. The offering is expected to close on or about
May 15, 2013
, subject to satisfaction of customary closing conditions. In addition, the underwriter has been granted a 30-day option to purchase up to an additional 1.425 million shares of common stock to cover over-allotments, if any. Stifel is acting as the sole book-running manager for the offering.
The securities described above are being offered by Discovery Laboratories, Inc. pursuant to a shelf registration statement on Form S-3, together with a base prospectus, previously filed and declared effective by the Securities and Exchange Commission (SEC). The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement related to the offering was filed with the SEC on May 9, 2013. When available, copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the Securities and Exchange Commission web site at
, or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate,
One Montgomery Street
, Suite 3700,
San Francisco, California
94104 or via telephone at (415) 364-2500.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Discovery Laboratories, Inc. nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.